First Implantation of Barricaid Device via Endoscopic Method
Intrinsic Therapeutics has recently made headlines by successfully implanting the Barricaid Annular Closure Device for the first time using an endoscopic approach. This advancement represents a significant milestone in the field of spine surgery, particularly focused on enhancing the care provided to lumbar discectomy patients who suffer from large annular defects. The goal of this innovative procedure is to drastically minimize the rate of reoperations for reherniations, which the Barricaid device has been shown to reduce by an impressive 81%.
Details of the Landmark Procedure
Renowned spine surgeon, Dr. Daniel E. Choi, MD, FAAOS, conducted this groundbreaking procedure at Gramercy Surgery Center. Utilizing his extensive experience and training, Dr. Choi exemplified how the integration of advanced technologies can redefine surgical standards. He noted, "This novel endoscopic approach to spine surgery enabled direct visualization during the discectomy and implantation of Barricaid. I am grateful that these technologies allow for harmonious integration and see this as the next advancement in patient care."
Integration of Techniques Brings Encouraging Results
Intrinsic's Chief Technology Officer, Jacob Einhorn, was present during the case and expressed his satisfaction with the seamless integration of the dualPortal® endoscopic method with the delivery of the Barricaid device. His reflections highlight the importance of maintaining standard procedural steps while ensuring the best outcomes for patients. He remarked, "For surgeons who prefer an endoscopic approach, Barricaid can preserve their discectomy outcomes and greatly reduce the risk of reherniation and reoperation." This forward-thinking technology empowers healthcare providers to enhance patient safety and return to health.
A Powerful Collaboration to Enhance Patient Care
This surgical case is particularly noteworthy as it marks the first instance of Barricaid being implanted into a patient via Amplify Surgical's dualPortal system. Andy Choi, CEO and Co-Founder of Amplify Surgical, commented on the collaboration, stating, "I am very pleased to see two unique products come together to help patients in ways never before demonstrated. By using dualPortal access, surgeons can broaden their selection of procedures performed in conjunction with an endoscope. We are extremely excited to add Barricaid to that list and look forward to continuing to support this cutting-edge combination."
Understanding the Barricaid Device and Its Impact
Barricaid is a proprietary technology specifically designed to prevent reherniation and subsequent reoperations in patients who undergo lumbar discectomy surgery with large annular defects. Over 12,000 patients have already benefited from this innovative device, which is backed by comprehensive clinical studies across a variety of patient populations. These studies include two randomized controlled trials and six single-arm investigations, demonstrating the effectiveness of Barricaid in enhancing post-operative outcomes. A notable multicenter, Level I randomized controlled trial has shown superior results when compared to discectomy alone, published in a prestigious medical journal with five-year follow-up findings.
*Note that some studies are conducted outside FDA indications; values were observed at a minimum of one year post-operation, with a minimum study size of 20 Barricaid subjects.
Frequently Asked Questions
What is the Barricaid Annular Closure Device?
The Barricaid device is designed to prevent reherniation and reduce the need for reoperations in patients who have undergone lumbar discectomy surgery.
How does the endoscopic approach benefit surgery?
This method allows for direct visualization during the surgery, enhancing precision and minimizing invasiveness, ultimately improving patient outcomes.
Why is the dualPortal® approach significant?
The dualPortal® method integrates seamlessly with the Barricaid device, allowing surgeons greater flexibility in performing procedures while maintaining typical operational standards.
Who performed the first implantation of the Barricaid device?
The procedure was conducted by Dr. Daniel E. Choi, a skilled orthopaedic spine surgeon committed to advancing patient care.
What is the track record of the Barricaid device?
Barricaid has been implanted in over 12,000 patients and has shown promising results in clinical studies, demonstrating its effectiveness and safety.
